

Effect of topical honey application along with intralesional injection of glucantime in the treatment of the cutaneous leishmaniasis

Submission date
10/09/2006

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
13/11/2006

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
23/01/2020

Condition category
Infections and Infestations

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Mohhamad Ali Nilfroushzadeh

Contact details

Skin Disease and Leishmaniasis Research Center (SDLRC)

Sedighe Tahereh Research & Therapeutic Center

Isfahan University of Medical Sciences

Isfahan

Iran

81876-98191

-

sdllrc@mui.ac.ir

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Effect of topical honey application along with intralesional injection of glucantime in the treatment of the cutaneous leishmaniasis

Study objectives

Topical honey along with intralesional glucantime is more effective in the treatment of the cutaneous leishmaniasis than intralesional glucantime alone.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study was approved by the ethics committee of the Skin Disease and Leishmaniasis Research Center (reference number: SEC. 84210).

Study design

This study was a controlled randomised clinical trial study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Cutaneous leishmaniasis

Interventions

Topical honey along with intralesional glucantime versus intralesional glucantime alone.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Topical honey and intralesional glucantime

Primary outcome measure

Curing of the leishmaniasis

Secondary outcome measures

Diameter of the lesion and size of the erythema, induration and ulcer

Overall study start date

21/12/2004

Completion date

22/10/2005

Eligibility

Key inclusion criteria

1. Confirmed cutaneous leishmaniasis with direct smear
2. No history of systemic or topical therapy for cutaneous leishmaniasis
3. Absence of the malnutrition or severe predisposing disease such as cardiac, renal or hepatic disease and other contraindication for glucantime

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

100

Key exclusion criteria

N/A

Date of first enrolment

21/12/2004

Date of final enrolment

22/10/2005

Locations

Countries of recruitment

Iran

Study participating centre

Skin Disease and Leishmaniasis Research Center (SDLRC)

Isfahan

Iran

81876-98191

Sponsor information

Organisation

Skin Disease and Leishmaniasis Research Center (Iran)

Sponsor details

Sedighe Tahereh Research & Theraputic Center

Khoram Street

Jomhory Square

Isfahan

Iran

81876-98191

-

sdlrc@mui.ac.ir

Sponsor type

Research organisation

ROR

<https://ror.org/04waqzz56>

Funder(s)

Funder type

University/education

Funder Name

Isfahan University of Medical Sciences, Skin Diseases and Leishmaiasis Research Center (Iran)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results:	27/04/2007		Yes	No